2,087 Shares in Amgen Inc. $AMGN Bought by WESPAC Advisors LLC

WESPAC Advisors LLC acquired a new stake in Amgen Inc. (NASDAQ:AMGN) in the fourth quarter, HoldingsChannel reports. The institutional investor acquired 2,087 shares of the medical research company’s stock, valued at approximately $683,000.

Several other institutional investors have also modified their holdings of the business. Brighton Jones LLC raised its holdings in Amgen by 23.5% in the fourth quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company’s stock valued at $7,159,000 after acquiring an additional 5,226 shares in the last quarter. Sivia Capital Partners LLC lifted its position in shares of Amgen by 10.6% during the second quarter. Sivia Capital Partners LLC now owns 1,186 shares of the medical research company’s stock worth $331,000 after purchasing an additional 114 shares during the last quarter. Schnieders Capital Management LLC. grew its stake in Amgen by 29.3% in the second quarter. Schnieders Capital Management LLC. now owns 25,859 shares of the medical research company’s stock worth $7,220,000 after purchasing an additional 5,853 shares in the last quarter. Elevation Point Wealth Partners LLC raised its stake in Amgen by 15.2% during the second quarter. Elevation Point Wealth Partners LLC now owns 857 shares of the medical research company’s stock valued at $239,000 after buying an additional 113 shares in the last quarter. Finally, Grantham Mayo Van Otterloo & Co. LLC grew its position in shares of Amgen by 12.8% in the 2nd quarter. Grantham Mayo Van Otterloo & Co. LLC now owns 4,245 shares of the medical research company’s stock worth $1,185,000 after acquiring an additional 481 shares in the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the stock. Wells Fargo & Company lifted their price objective on shares of Amgen from $375.00 to $390.00 and gave the stock an “equal weight” rating in a report on Thursday, March 19th. Mizuho increased their price target on Amgen from $280.00 to $295.00 and gave the stock an “outperform” rating in a research report on Tuesday, February 10th. BMO Capital Markets upped their price objective on Amgen from $335.00 to $372.00 and gave the stock an “outperform” rating in a research note on Wednesday, December 3rd. TD Cowen reiterated a “buy” rating on shares of Amgen in a research note on Wednesday, February 4th. Finally, HSBC reaffirmed a “buy” rating and issued a $425.00 price objective on shares of Amgen in a report on Wednesday, December 10th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, thirteen have issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $354.60.

Amgen Price Performance

Shares of NASDAQ:AMGN opened at $348.77 on Monday. The company has a debt-to-equity ratio of 5.78, a current ratio of 1.14 and a quick ratio of 0.90. The stock has a market cap of $188.01 billion, a price-to-earnings ratio of 24.51, a PEG ratio of 3.46 and a beta of 0.45. The stock’s 50 day moving average price is $362.59 and its 200 day moving average price is $330.59. Amgen Inc. has a 12 month low of $261.43 and a 12 month high of $391.29.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.76 by $0.53. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The company had revenue of $9.87 billion for the quarter, compared to analysts’ expectations of $9.46 billion. During the same quarter in the previous year, the company posted $5.31 EPS. The business’s revenue was up 8.6% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. Equities research analysts anticipate that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, June 5th. Shareholders of record on Friday, May 15th will be issued a $2.52 dividend. The ex-dividend date of this dividend is Friday, May 15th. This represents a $10.08 annualized dividend and a dividend yield of 2.9%. Amgen’s dividend payout ratio is currently 70.84%.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.